Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director February 11, 2026
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites February 2, 2026
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad January 21, 2026
Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patients October 23, 2025
James Mackay is tending to ‘unfinished business’ with new gout biotech and $205M fundraise September 30, 2025
Crystalys lands $205M to bring gout drug first marketed in Japan to the US and Europe September 30, 2025
